GlassScriptPhysician profile
Stephen R Conway
NPI 1104866524
$8,302.47
in general payments reported to CMS, 2019-2025
55 companies · $17.37 in 2025
The $17.37 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,921 · 2020: $1,130 · 2021: $1,420 · 2022: $1,461 · 2023: $2,336 · 2024: $17.71 · 2025: $17.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $668.35 | 2019-2023 | |
| Biogen, INC. | $666.47 | 2019-2023 | Vumerity, Tysabri, Aduhelm |
| Abbvie INC. | $577.30 | 2021-2023 | Qulipta, Duopa, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $521.17 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $352.48 | 2019-2023 | Ultomiris, Soliris |
| Amneal Pharmaceuticals LLC | $322.76 | 2019-2023 | Rytary |
| Teva Pharmaceuticals USA, INC. | $293.38 | 2019-2023 | Austedo, Ajovy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $281.24 | 2019-2022 | |
| Emd Serono, INC. | $279.67 | 2019-2023 | Mavenclad |
| Allergan, INC. | $268.10 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $219.26 | 2019-2021 | |
| Ge Healthcare | $210.70 | 2020-2023 | |
| Acorda Therapeutics, INC | $199.10 | 2019-2020 | |
| Pfizer INC. | $179.42 | 2021-2023 | |
| Sk Life Science, INC. | $179.41 | 2021-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Conway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.